ArticleFrontiers in pharmacology2025
Study on the mechanism of no. 8 burn ointment in burn treatment based on network pharmacology and experimental verification.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GM-CSF and IL-1α secreted by cryopreserved porcine skin promote angiogenesis in burn wounds by activating the JAK2/STAT3 pathway.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: As a traditional Chinese compound formulation, No.8 burn ointment has demonstrated notable efficacy over half a century of clinical use, particularly in facilitating the healing of burn wounds. Methods: This study integrates clinical data, liquid chromatography-mass spectrometry, network pharmacology and experimental validation to elucidate the mechanisms by which No.8 burn ointment promotes burn wound healing and to identify its key active components. Results: The findings reveal that the ointment may accelerate wound repair by modulating the HIF-1 signaling pathway. The network pharmacology analysis has identified HIF-1α as a core target of the No.8 burn ointment's action and has identified the key active molecules β-Elemonic acid and Rubiadin, which interact with the HIF-1α protein and influence the HIF-1 pathway. Conclusion: This research not only provides a theoretical foundation for the selection of targeted drugs in burn treatment and the optimization of traditional Chinese compounds but also provides new ideas for future research in related fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.